Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
Intervention and mechanism of Xiaoyin Anshen Yin in treatment of psoriasis combined with sleep disorders.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ruohan Diao, Xingwu Duan, Lingling L I, Tiange Q U, Huishang Feng, Guangshan Chen
Аннотация
OBJECTIVE: To explore the therapeutic mechanisms of Xiaoyin Anshen Yin (, XYAS) in treating psoriasis associated with sleep focusing on melatonin and the regulation of the nuclear factor kappa-B (NF-κB) pathway.
METHODS: Forty Sprague-Dawley rats were randomly divided into four groups, and administered distilled water, XYAS and its two different disassembly prescriptions by gavage respectively. Four types of drug-containing serums corresponding to the four groups were then prepared. Tumor necrosis factor (TNF)-α stimulated HaCaT was used to establish a psoriasis cell model, and the serums and the retinoid related orphan receptor alpha (RORα) inverse agonist were used respectively to intervene in the model. Enzyme-linked immunosorbent assay was used to detect the levels of interleukin (IL)-6 and melatonin in each group; flow cytometry was used to detect the levels of reactive oxygen species (ROS), mitochondrial membrane potential, and apoptosis; Western blot was used to evaluate the levels of superoxide dismutase 2 (SOD2), cytochrome-c (Cyt-c), inhibitor of kappa-B alpha (IκBα), p65 and phosphorylated p65.
RESULTS: XYAS and its disassembly prescriptions inhibited the secretion of inflammatory factors such as IL-6, reduced the ROS content and Cyt-c expression, increased the mitochondrial membrane potential and SOD2 content, promoted the apoptosis in HaCaT cells and inhibited the activation of the NF-κB pathway. XYAS was also found increase the melatonin content. The above effects are beneficial in the treatment of psoriasis combined with sleep disorders. Meanwhile, XYAS no longer had a significant ameliorative effect after applying the RORα inverse agonist, suggesting that the therapeutic effect of XYAS is related to RORα.
CONCLUSIONS: The results of this study confirm that XYAS can be utilized for the treatment of psoriasis combined with sleep disorders via inhibiting the NF-κB pathway, anti-inflammatory, antioxidant and pro-apoptotic, which is in part related to the regulatory role of melatonin and its receptor RORα.
METHODS: Forty Sprague-Dawley rats were randomly divided into four groups, and administered distilled water, XYAS and its two different disassembly prescriptions by gavage respectively. Four types of drug-containing serums corresponding to the four groups were then prepared. Tumor necrosis factor (TNF)-α stimulated HaCaT was used to establish a psoriasis cell model, and the serums and the retinoid related orphan receptor alpha (RORα) inverse agonist were used respectively to intervene in the model. Enzyme-linked immunosorbent assay was used to detect the levels of interleukin (IL)-6 and melatonin in each group; flow cytometry was used to detect the levels of reactive oxygen species (ROS), mitochondrial membrane potential, and apoptosis; Western blot was used to evaluate the levels of superoxide dismutase 2 (SOD2), cytochrome-c (Cyt-c), inhibitor of kappa-B alpha (IκBα), p65 and phosphorylated p65.
RESULTS: XYAS and its disassembly prescriptions inhibited the secretion of inflammatory factors such as IL-6, reduced the ROS content and Cyt-c expression, increased the mitochondrial membrane potential and SOD2 content, promoted the apoptosis in HaCaT cells and inhibited the activation of the NF-κB pathway. XYAS was also found increase the melatonin content. The above effects are beneficial in the treatment of psoriasis combined with sleep disorders. Meanwhile, XYAS no longer had a significant ameliorative effect after applying the RORα inverse agonist, suggesting that the therapeutic effect of XYAS is related to RORα.
CONCLUSIONS: The results of this study confirm that XYAS can be utilized for the treatment of psoriasis combined with sleep disorders via inhibiting the NF-κB pathway, anti-inflammatory, antioxidant and pro-apoptotic, which is in part related to the regulatory role of melatonin and its receptor RORα.